Piedmont Investment Advisors LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 198,644 shares of the medical research company’s stock, valued at approximately $33,136,000.
Other institutional investors have also recently bought and sold shares of the company. BlackRock Institutional Trust Company N.A. raised its position in Amgen by 1.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 20,435,310 shares of the medical research company’s stock worth $3,109,232,000 after buying an additional 271,591 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of Amgen by 1.1% in the third quarter. BlackRock Fund Advisors now owns 13,112,904 shares of the medical research company’s stock worth $2,187,364,000 after buying an additional 141,076 shares in the last quarter. Northern Trust Corp raised its position in shares of Amgen by 2.5% in the third quarter. Northern Trust Corp now owns 9,573,235 shares of the medical research company’s stock worth $1,596,911,000 after buying an additional 234,821 shares in the last quarter. Morgan Stanley raised its position in shares of Amgen by 8.0% in the third quarter. Morgan Stanley now owns 8,678,786 shares of the medical research company’s stock worth $1,447,708,000 after buying an additional 639,410 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Amgen by 2.0% in the third quarter. Nordea Investment Management AB now owns 5,830,858 shares of the medical research company’s stock worth $972,645,000 after buying an additional 111,690 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.66 on Tuesday. The company has a market capitalization of $123.73 billion, a PE ratio of 16.37 and a beta of 1.15. The stock has a 50 day moving average of $156.95 and a 200-day moving average of $159.18. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $176.85.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 2nd. The medical research company reported $2.89 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.10. The business had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.61 earnings per share. Analysts predict that Amgen Inc. will post $12.34 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 8th. Investors of record on Wednesday, February 15th will be paid a dividend of $1.15 per share. The ex-dividend date of this dividend is Monday, February 13th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.74%. This is a positive change from Amgen’s previous quarterly dividend of $1.00. Amgen’s dividend payout ratio (DPR) is presently 39.06%.
This article was published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be accessed at http://sleekmoney.com/198644-shares-in-amgen-inc-amgn-acquired-by-piedmont-investment-advisors-llc/1659702.html.
A number of equities analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. set a $175.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Thursday, February 2nd. BMO Capital Markets upped their target price on shares of Amgen to $212.00 in a research report on Monday. Leerink Swann restated a “market perform” rating and set a $163.00 target price (down previously from $193.00) on shares of Amgen in a research report on Friday, October 28th. Credit Suisse Group restated a “hold” rating and set a $178.00 target price on shares of Amgen in a research report on Sunday, February 5th. Finally, Mizuho restated a “buy” rating on shares of Amgen in a research report on Wednesday, February 8th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $181.90.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/198644-shares-in-amgen-inc-amgn-acquired-by-piedmont-investment-advisors-llc/1659702.html
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.